S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Forecast & News

$12.22
-0.35 (-2.78 %)
(As of 02/17/2020 04:00 PM ET)
Today's Range
$11.72
Now: $12.22
$12.91
50-Day Range
$8.92
MA: $10.41
$13.45
52-Week Range
$6.07
Now: $12.22
$18.08
Volume32.78 million shs
Average Volume21.13 million shs
Market Capitalization$13.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.89 billion
Cash Flow$4.63 per share
Book Value$15.53 per share

Profitability

Net Income$-2,150,000,000.00

Miscellaneous

Employees42,535
Outstanding Shares1,092,090,000
Market Cap$13.35 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.


Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its earnings results on Wednesday, February, 12th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.61 by $0.01. The company earned $4.47 billion during the quarter, compared to the consensus estimate of $4.35 billion. Teva Pharmaceutical Industries had a negative net margin of 5.75% and a positive return on equity of 16.49%. The company's revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.53 EPS. View Teva Pharmaceutical Industries' Earnings History.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, February, 12th. The company provided EPS guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.47. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $17.14 billion.

What price target have analysts set for TEVA?

23 equities research analysts have issued 1 year price objectives for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.60 in the next year. This suggests that the stock has a possible downside of 5.1%. View Analyst Price Targets for Teva Pharmaceutical Industries.

What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Media stories about TEVA stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Teva Pharmaceutical Industries.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:
  • Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 48)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (1.82%), Migdal Insurance & Financial Holdings Ltd. (1.16%), Menora Mivtachim Holdings LTD. (0.77%), Commerzbank Aktiengesellschaft FI (0.72%), Harel Insurance Investments & Financial Services Ltd. (0.49%) and Sumitomo Mitsui Trust Holdings Inc. (0.37%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Renaissance Technologies LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Commerzbank Aktiengesellschaft FI, Acadian Asset Management LLC, Caisse DE Depot ET Placement DU Quebec, Cubist Systematic Strategies LLC and Oxford Asset Management LLP. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Hafrun Fridriksdottir, Luzich Partners Llc, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was purchased by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Migdal Insurance & Financial Holdings Ltd., Harel Insurance Investments & Financial Services Ltd., Banco Bilbao Vizcaya Argentaria S.A., Beck Mack & Oliver LLC, Van ECK Associates Corp, UBS Asset Management Americas Inc. and Virtu Financial LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $12.22.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $13.35 billion and generates $16.89 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,258 (Vote Outperform)
Underperform Votes:  1,157 (Vote Underperform)
Total Votes:  2,415
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Cash Flow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel